OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
OKYO Pharma Limited - American Depositary Shares (OKYO)
Company Research
Source: GlobeNewswire
LONDON and NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced new positive findings from an exploratory analysis of patient-reported outcomes in its recently completed Phase 2a trial of urcosimod (0.05%) for the treatment of NCP. This new quality-of-life (QoL) data will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting. The presentation, titled: “First-in-Human Study of Urcosimod to Treat Neuropathic Corneal Pain (NCP) Shows Clinically Meaningful Pain Reduction and Quality-of-Life Improvement in NCP Patients” will detail the Phase 2a clinical trial results, including reductions in pain as measured by the VAS, improvements in patient-reported QoL measures, as well as signals suggesting potential restoration of corneal nerve s
Show less
Read more
Impact Snapshot
Event Time:
OKYO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OKYO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OKYO alerts
High impacting OKYO Pharma Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
OKYO
News
- OKYO Pharma Announces Director Acquires Shares [Yahoo! Finance]Yahoo! Finance
- OKYO Pharma Announces Chairman and Founder Acquires SharesGlobeNewswire
- OKYO Pharma Announces Director Acquires SharesGlobeNewswire
- OKYO Pharma Announces Chief Development Officer and Director Acquires SharesGlobeNewswire
- OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial [Yahoo! Finance]Yahoo! Finance
OKYO
Analyst Actions
- 1/29/26 - HC Wainwright
OKYO
Sec Filings
- 3/19/26 - Form 6-K
- 3/19/26 - Form 6-K
- 3/19/26 - Form 6-K
- OKYO's page on the SEC website